在不稳定性胸痛中,罪祸首病变的血管活性
P Bogaty1, D Hackett, G Davies
1Cardiovascular Research Unit, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK.
Circulation
|July 1, 1994
概括
在挑性测试中,不稳定性 angina 中的罪祸首的病变比稳定性 angina 病变缩小得多. 这种异常的血管活性可能标志着或倾向于复发性急性缺血.
科学领域:
- 心脏病学 心脏病学
- 血管生物学 血管生物学
- 缺血性心脏病是一种心脏病.
背景情况:
- 异常血管收缩与急性冠状动脉综合征有关.
- 不稳定性 angina culprit 病变的血管活性仍未得到研究.
- 目前尚不清楚增强的血管活性是否超出了罪祸首的损伤范围.
研究的目的:
- 为了调查不稳定性胸痛中罪祸首病变的血管活性.
- 为了比较罪祸首病变的血管活性与稳定的胸痛病变.
- 评估远距离和不涉及的冠状动脉中的血管活性.
主要方法:
- 定量冠状动脉血管学在7名不稳定性心痛患者和7名稳定性心痛对照中使用.
- 挑性刺激包括人体力学自行车运动和冷压器测试.
- 测量了罪祸首病变的光线直径,远端段和不涉及的动脉.
主要成果:
- 不稳定性心痛中的罪祸首病变在运动和冷压力测试中显著缩小.
- 随着炼,罪祸首病变的直径从1.41毫米减少到1.09毫米 (P=.001).
- 稳定性胸痛控制病变在具有挑性的刺激时,直径没有显著变化.
结论:
- 与稳定的心痛病变相比,不稳定的心痛罪祸首病变表现出增加的血管活性.
- 在不涉及或远端冠状动脉段中没有观察到显著的血管活性.
- 在罪祸首病变部位的异常血管活性可能表明或倾向于复发性缺血症.
相关概念视频
Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Angina II: Classification
Angina, also known as angina pectoris, is a chest pain resulting from diminished blood flow to the heart muscle and is often a symptom of coronary artery disease. Angina presents several variants with distinctive attributes, etiologies, and therapeutic approaches. The main types of angina include stable, unstable, variant (Prinzmetal's), microvascular, intractable, and silent ischemia.Stable angina is caused by atherosclerosis, which leads to the formation of plaques that narrow the coronary...
Angina III: Clinical Manifestations and Assessment
Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...
Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Angina V: Nursing Management
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...


